CAR T-cell therapy Market Growth and Status Explored in a New Research Report 2035
Cancer therapeutics continue to be one of the most active areas, in terms of drug development, there is still a significant unmet need in this domain. In fact, conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers.
The global CAR T-cell therapy market size is projected to grow from USD 4.6 billion in 2024 to USD 15.2 billion by 2035, growing at a CAGR of 11.4% during the period, till 2035.
Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to selectively eliminate tumor cells with minimal side effects.
Immunotherapies essentially make use of the body’s own immune system, or its components, to fight cancer. It is a relatively new concept, currently having achieved pharmacological success with targeted antibody-based therapeutics, including monoclonal and conjugated antibodies. However, over the years, different classes of immunotherapies have emerged for the management and treatment of cancer; these include therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors and certain whole cell-based therapies (adoptive cell therapies).
The CAR T cell therapy market landscape has transformed significantly over the past two decades. Currently, more than 330 players claim to provide CAR-T cell therapies across different developed geographies. More than 75% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature. Further, CD19 and BCMA have emerged as the most popular target antigens.
A rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain; maximum number of such deals were signed in 2021. Majority of the partnership instances are intracontinental. Additionally, close to 50% of the total number of partnerships have been signed between the players based in North America. Further, for majority of the intercontinental agreements, companies headquartered in Europe have collaborated with players based in North America.
Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested close to USD 32.4 billion, across 260+ instances, during the period pre2014-2024.
Majority of the patents in this domain are patent applications (84%), followed by granted patents (13%). In addition, most of the patents (54%) were filed / granted in North America. This is followed by patents filed / granted in Europe (19%).
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Car T-cell therapy Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/car-t-cell-therapy-market/269.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
Sales@rootsanalysis.com
Cancer therapeutics continue to be one of the most active areas, in terms of drug development, there is still a significant unmet need in this domain. In fact, conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers.
The global CAR T-cell therapy market size is projected to grow from USD 4.6 billion in 2024 to USD 15.2 billion by 2035, growing at a CAGR of 11.4% during the period, till 2035.
Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to selectively eliminate tumor cells with minimal side effects.
Immunotherapies essentially make use of the body’s own immune system, or its components, to fight cancer. It is a relatively new concept, currently having achieved pharmacological success with targeted antibody-based therapeutics, including monoclonal and conjugated antibodies. However, over the years, different classes of immunotherapies have emerged for the management and treatment of cancer; these include therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors and certain whole cell-based therapies (adoptive cell therapies).
The CAR T cell therapy market landscape has transformed significantly over the past two decades. Currently, more than 330 players claim to provide CAR-T cell therapies across different developed geographies. More than 75% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature. Further, CD19 and BCMA have emerged as the most popular target antigens.
A rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain; maximum number of such deals were signed in 2021. Majority of the partnership instances are intracontinental. Additionally, close to 50% of the total number of partnerships have been signed between the players based in North America. Further, for majority of the intercontinental agreements, companies headquartered in Europe have collaborated with players based in North America.
Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested close to USD 32.4 billion, across 260+ instances, during the period pre2014-2024.
Majority of the patents in this domain are patent applications (84%), followed by granted patents (13%). In addition, most of the patents (54%) were filed / granted in North America. This is followed by patents filed / granted in Europe (19%).
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Car T-cell therapy Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/car-t-cell-therapy-market/269.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
Sales@rootsanalysis.com
CAR T-cell therapy Market Growth and Status Explored in a New Research Report 2035
Cancer therapeutics continue to be one of the most active areas, in terms of drug development, there is still a significant unmet need in this domain. In fact, conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers.
The global CAR T-cell therapy market size is projected to grow from USD 4.6 billion in 2024 to USD 15.2 billion by 2035, growing at a CAGR of 11.4% during the period, till 2035.
Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to selectively eliminate tumor cells with minimal side effects.
Immunotherapies essentially make use of the body’s own immune system, or its components, to fight cancer. It is a relatively new concept, currently having achieved pharmacological success with targeted antibody-based therapeutics, including monoclonal and conjugated antibodies. However, over the years, different classes of immunotherapies have emerged for the management and treatment of cancer; these include therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors and certain whole cell-based therapies (adoptive cell therapies).
The CAR T cell therapy market landscape has transformed significantly over the past two decades. Currently, more than 330 players claim to provide CAR-T cell therapies across different developed geographies. More than 75% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature. Further, CD19 and BCMA have emerged as the most popular target antigens.
A rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain; maximum number of such deals were signed in 2021. Majority of the partnership instances are intracontinental. Additionally, close to 50% of the total number of partnerships have been signed between the players based in North America. Further, for majority of the intercontinental agreements, companies headquartered in Europe have collaborated with players based in North America.
Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested close to USD 32.4 billion, across 260+ instances, during the period pre2014-2024.
Majority of the patents in this domain are patent applications (84%), followed by granted patents (13%). In addition, most of the patents (54%) were filed / granted in North America. This is followed by patents filed / granted in Europe (19%).
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Car T-cell therapy Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/car-t-cell-therapy-market/269.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
Sales@rootsanalysis.com
0 Comments
0 Shares